Literature DB >> 30902831

The PKR-Like Endoplasmic Reticulum Kinase Promotes the Dissemination of Myc-Induced Leukemic Cells.

Jun Gui1, Kanstantsin V Katlinski1, Constantinos Koumenis2, J Alan Diehl3, Serge Y Fuchs4.   

Abstract

Hyperactive oncogenic Myc stimulates protein synthesis that induces the unfolded protein response, which requires the function of the eukaryotic translation initiation factor 2-alpha kinase 3, also known as protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). Activated PERK acts to limit mRNA translation, enable proper protein folding, and restore the homeostasis in the endoplasmic reticulum. Given that Myc activation contributes to many types of lymphoid and myeloid human leukemias, we used a mouse model to examine the importance of PERK in development and progression of Myc-induced leukemias. We found that genetic ablation of Perk does not suppress the generation of the leukemic cells in the bone marrow. However, the cell-autonomous Perk deficiency restricts the dissemination of leukemic cells into peripheral blood, lymph nodes, and vital peripheral organs. Whereas the loss of the IFNAR1 chain of type I IFN receptor stimulated leukemia, Perk ablation did not stabilize IFNAR1, suggesting that PERK stimulates the leukemic cells' dissemination in an IFNAR1-independent manner. We discuss the rationale for using PERK inhibitors against Myc-driven leukemias. IMPLICATIONS: The role of PERK in dissemination of Myc-induced leukemic cells demonstrated in this study argues for the use of PERK inhibitors against leukemia progression. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30902831      PMCID: PMC6610583          DOI: 10.1158/1541-7786.MCR-19-0002

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  47 in total

1.  Ligand-independent pathway that controls stability of interferon alpha receptor.

Authors:  Jianghuai Liu; Alexander Plotnikov; Anamika Banerjee; K G Suresh Kumar; Josiane Ragimbeau; Zrinka Marijanovic; Darren P Baker; Sandra Pellegrini; Serge Y Fuchs
Journal:  Biochem Biophys Res Commun       Date:  2007-12-31       Impact factor: 3.575

2.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

3.  miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner.

Authors:  Nilesh S Chitnis; Dariusz Pytel; Ekaterina Bobrovnikova-Marjon; Dhruv Pant; Hui Zheng; Nancy L Maas; Brian Frederick; Jake A Kushner; Lewis A Chodosh; Constantinos Koumenis; Serge Y Fuchs; J Alan Diehl
Journal:  Mol Cell       Date:  2012-09-27       Impact factor: 17.970

4.  Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor.

Authors:  Sabyasachi Bhattacharya; Juan Qian; Christos Tzimas; Darren P Baker; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2011-05-03       Impact factor: 5.157

5.  SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor.

Authors:  K G Suresh Kumar; Weigang Tang; Abhilash K Ravindranath; William A Clark; Ed Croze; Serge Y Fuchs
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

Review 6.  Galectins as regulators of cell survival in the leukemia niche.

Authors:  Peter P Ruvolo
Journal:  Adv Biol Regul       Date:  2018-09-12

Review 7.  Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.

Authors:  Serge Y Fuchs
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

8.  Signaling through alternative Integrated Stress Response pathways compensates for GCN2 loss in a mouse model of soft tissue sarcoma.

Authors:  Stacey L Lehman; Sandra Ryeom; Constantinos Koumenis
Journal:  Sci Rep       Date:  2015-06-30       Impact factor: 4.379

Review 9.  Tumor progression and the different faces of the PERK kinase.

Authors:  D Pytel; I Majsterek; J A Diehl
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

10.  PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.

Authors:  Dariusz Pytel; Yan Gao; Katarzyna Mackiewicz; Yuliya V Katlinskaya; Kirk A Staschke; Maria C G Paredes; Akihiro Yoshida; Shuo Qie; Gao Zhang; Olga S Chajewski; Lawrence Wu; Ireneusz Majsterek; Meenhard Herlyn; Serge Y Fuchs; J Alan Diehl
Journal:  PLoS Genet       Date:  2016-12-15       Impact factor: 5.917

View more
  2 in total

Review 1.  Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities.

Authors:  Ali Khateb; Ze'ev A Ronai
Journal:  Trends Cancer       Date:  2020-06-13

2.  Overexpression of HOXA10 is associated with unfavorable prognosis of acute myeloid leukemia.

Authors:  Chao Guo; Qian-Qian Ju; Chun-Xia Zhang; Ming Gong; Zhen-Ling Li; Ya-Yue Gao
Journal:  BMC Cancer       Date:  2020-06-22       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.